Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: Association with oligoclonal IgM bands and prediction of multiple sclerosis diagnosis

Journal of Neuroimmunology

Volumn 283, Issue , 2015, Pages 64-69

  Ferraro, Diana ^a   Galli, Veronica ^a   Vitetta, Francesca ^a   Simone, Anna Maria ^a   Bedin, Roberta ^a   Del Giovane, Cinzia ^a   Morselli, Franca ^a   Filippini, Maria Maddalena ^a   Nichelli, Paolo Frigio ^a   Sola, Patrizia ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Cerebrospinal fluid; Clinically isolated syndrome; CXCL13; IgM oligoclonal bands; Multiple sclerosis; Relapsing remitting

Indexed keywords

CXCL13 CHEMOKINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; OLIGOCLONAL BAND; PROTEIN; CXCL13 PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD ANALYSIS; CELL COUNT; CEREBROSPINAL FLUID ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; DEMYELINATING DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE COURSE; EARLY DIAGNOSIS; FEMALE; HUMAN; IMMUNOGLOBULIN G INDEX; IMMUNOLOGICAL PARAMETERS; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PUNCTURE; RECURRENCE FREE SURVIVAL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; BLOOD; BRAIN; CEREBROSPINAL FLUID; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; SPINAL CORD; YOUNG ADULT;

ADULT; BRAIN; CHEMOKINE CXCL13; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OLIGOCLONAL BANDS; PREDICTIVE VALUE OF TESTS; RECURRENCE; RISK FACTORS; SPINAL CORD; YOUNG ADULT;

EID: 84929594026     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2015.04.011     Document Type: Article

References (35)

1. Alvarez E., Piccio L., Mikesell R.J., Klawiter E.C., Parks B.J., Naismith R.T., Cross A.H. CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions. Mult. Scler. 2013, 19:1204-1208. 10.1177/1352458512473362.
2. Bagaeva L.V., Rao P., Powers J.M., Segal B.M. CXC chemokine ligand 13 plays a role in experimental autoimmune encephalomyelitis. J. Immunol. 2006, 176:7676-7685.
3. Boscá I., Magraner M.J., Coret F., Alvarez-Cermeño J.C., Simó-Castelló M., Villar L.M., Casanova B. The risk of relapse after a clinically isolated syndrome is related to the pattern of oligoclonal bands. J. Neuroimmunol. 2010, 226:143-146. 10.1016/j.jneuroim.2010.05.032.
4. Brettschneider J., Czerwoniak A., Senel M., Fang L., Kassubek J., Pinkhardt E., Lauda F., Kapfer T., Jesse S., Lehmensiek V., Ludolph A.C., Otto M., Tumani H. The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). PLoS One 2010, 5:e11986. 10.1371/journal.pone.0011986.
5. Corcione A., Casazza S., Ferretti E., Giunti D., Zappia E., Pistorio A., Gambini C., Mancardi G.L., Uccelli A., Pistoia V. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:11064-11069. 10.1073/pnas.0402455101.
6. Ferraro D., Simone A.M., Bedin R., Galli V., Vitetta F., Federzoni L., D'Amico R., Merelli E., Nichelli P.F., Sola P. Cerebrospinal fluid oligoclonal IgM bands predict early conversion to clinically definite multiple sclerosis in patients with Clinically Isolated Syndrome. J. Neuroimmunol. 2013, 257:76-81. 10.1016/j.jneuroim.2013.01.011.
7. Festa E.D., Hankiewicz K., Kim S., Skurnick J., Wolansky L.J., Cook S.D., Cadavid D. Serum levels of CXCL13 are elevated in active multiple sclerosis. Mult. Scler. 2009, 15:1271-1279. 10.1177/1352458509107017.
8. Gout O., Bouchareine A., Moulignier A., Deschamps R., Papeix C., Gorochov G., Héran F., Bastuji-Garin S. Prognostic value of cerebrospinal fluid analysis at the time of a first demyelinating event. Mult. Scler. 2011, 17:164-172. 10.1177/1352458510385506.
9. Khademi M., Kockum I., Andersson M.L., Iacobaeus E., Brundin L., Sellebjerg F., Hillert J., Piehl F., Olsson T. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult. Scler. 2011, 17:335-343. 10.1177/1352458510389102.
10. Kim C.H., Rott L.S., Clark-Lewis I., Campbell D.J., Wu L., Butcher E.C. Subspecialization of CXCR5+ T cells: B helper activity is focused in a germinal center-localized subset of CXCR5+ T cells. J. Exp. Med. 2001, 193:1373-1381.
11. Krumbholz M., Theil D., Cepok S., Hemmer B., Kivisäkk P., Ransohoff R.M., Hofbauer M., Farina C., Derfuss T., Hartle C., Newcombe J., Hohlfeld R., Meinl E. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 2006, 129:200-211. 10.1093/brain/awh680.
12. Kuenz B., Lutterotti A., Ehling R., Gneiss C., Haemmerle M., Rainer C., Deisenhammer F., Schocke M., Berger T., Reindl M. Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis. PLoS One 2008, 3:e2559.
13. Langenkamp A., Nagata K., Murphy K., Wu L., Lanzavecchia A., Sallusto F. Kinetics and expression patterns of chemokine receptors in human CD4+ T lymphocytes primed by myeloid or plasmacytoid dendritic cells. Eur. J. Immunol. 2003, 33:474-482. 10.1002/immu.200310023.
14. Leray E., Yaouanq J., Le Page E., Coustans M., Laplaud D., Oger J., Edan G. Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010, 133:1900-1913. 10.1093/brain/awq076.
15. Magliozzi R., Columba-Cabezas S., Serafini B., Aloisi F. Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2004, 148:11-23. 10.1016/j.jneuroim.2003.10.056.
16. Mandrioli J., Sola P., Bedin R., Gambini M., Merelli E. A multifactorial prognostic index in multiple sclerosis. Cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease. J. Neurol. 2008, 255:1023-1031. 10.1007/s00415-008-0827-5.
17. Mead R.J., Singhrao S.K., Neal J.W., Lassmann H., Morgan B.P. The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. J. Immunol. 2002, 168:458-465.
18. Meinl E., Krumbholz M., Hohlfeld R. B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann. Neurol. 2006, 59:880-892. 10.1002/ana.20890.
19. Optic F., Treatment N. Multiple sclerosis risk after optic neuritis. Brain 2008, 65:727-732.
20. Piccio L., Naismith R.T., Trinkaus K., Klein R.S., Parks B.J., Lyons J.A., Cross A.H. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch. Neurol. 2010, 67:707-714. 10.1001/archneurol.2010.99.
21. Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.a, Filippi M., Fujihara K., Havrdova E., Hutchinson M., Kappos L., Lublin F.D., Montalban X., O'Connor P., Sandberg-Wollheim M., Thompson A.J., Waubant E., Weinshenker B., Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 2011, 69:292-302. 10.1002/ana.22366.
22. Ragheb S., Li Y., Simon K., VanHaerents S., Galimberti D., De Riz M., Fenoglio C., Scarpini E., Lisak R. Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Mult. Scler. 2011, 17:819-829. 10.1177/1352458511398887.
23. Scalfari A., Neuhaus A., Degenhardt A., Rice G.P., Muraro P.a, Daumer M., Ebers G.C. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 2010, 133:1914-1929. 10.1093/brain/awq118.
24. Seidi O.a, Semra Y.K., Sharief M.K. Expression of CD5 on B lymphocytes correlates with disease activity in patients with multiple sclerosis. J. Neuroimmunol. 2002, 133:205-210.
25. Sellebjerg F., Börnsen L., Khademi M., Krakauer M., Olsson T., Frederiksen J.L., Sørensen P.S. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 2009, 73:2003-2010. 10.1212/WNL.0b013e3181c5b457.
26. Senel M., Tumani H., Lauda F., Presslauer S., Mojib-Yezdani R., Otto M., Brettschneider J. Cerebrospinal fluid immunoglobulin kappa light chain in clinically isolated syndrome and multiple sclerosis. PLoS One 2014, 9:e88680. 10.1371/journal.pone.0088680.
27. Sola P., Mandrioli J., Simone A.M., Ferraro D., Bedin R., Annecca R., Venneri M.G., Nichelli P.F., Merelli E. Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM. Mult. Scler. 2011, 17:303-311. 10.1177/1352458510386996.
28. Thangarajh M., Gomez-Rial J., Hedström a K., Hillert J., Alvarez-Cermeño J.C., Masterman T., Villar L.M. Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis. Mult. Scler. 2008, 14:1208-1213. 10.1177/1352458508095729.
29. Tintoré M., Rovira a, Río J., Nos C., Grivé E., Téllez N., Pelayo R., Comabella M., Sastre-Garriga J., Montalban X. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006, 67:968-972. 10.1212/01.wnl.0000237354.10144.ec.
30. Tintoré M., Rovira A., Río J., Tur C., Pelayo R., Nos C., Téllez N., Perkal H., Comabella M., Sastre-Garriga J., Montalban X. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?. Neurology 2008, 70:1079-1083. 10.1212/01.wnl.0000280576.73609.c6.
31. Villar L.M., González-Porqué P., Masjuán J., Alvarez-Cermeño J.C., Bootello a, Keir G. A sensitive and reproducible method for the detection of oligoclonal IgM bands. J. Immunol. Methods 2001, 258:151-155.
32. Villar L.M., Masjuan J., González-Porqué P., Plaza J., Sádaba M.C., Roldán E., Bootello A., Alvarez-Cermeño J.C. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology 2002, 59:555-559.
33. Villar L.M., Masjuan J., González-Porqué P., Plaza J., Sádaba M.C., Roldán E., Bootello A., Alvarez-Cermeño J.C. Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann. Neurol. 2003, 53:222-226. 10.1002/ana.10441.
34. Villar L.M., Sádaba M.C., Roldán E., Masjuan J., González-porqué P., Villarrubia N., Espiño M., García-trujillo J.A., Bootello A. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J. Clin. Investig. 2005, 115:187-194. 10.1172/JCI200522833.The.
35. Villar L.M., Espiño M., Cavanillas M.L., Roldán E., Urcelay E., de la Concha E.G., Sádaba M.C., Arroyo R., González-Porqué P., Alvarez-Cermeño J.C. Immunological mechanisms that associate with oligoclonal IgM band synthesis in multiple sclerosis. Clin. Immunol. 2010, 137:51-59. 10.1016/j.clim.2010.06.007.